<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00838227</url>
  </required_header>
  <id_info>
    <org_study_id>07I/C41-00</org_study_id>
    <nct_id>NCT00838227</nct_id>
  </id_info>
  <brief_title>Modafinil Augmentation in Chronic Schizophrenia and Schizoaffective Disorder</brief_title>
  <official_title>Modafinil Augmentation in Chronic Schizophrenia and Schizoaffective Disorder: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Manhattan Psychiatric Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Manhattan Psychiatric Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label 8-week trial of modafinil up to 400 mg daily added to a stable&#xD;
      antipsychotic regimen to evaluate the effect modafinil on cognition, sedation, and weight in&#xD;
      patients with chronic schizophrenia. We hypothesize that modafinil, a wake-promoting agent,&#xD;
      will lead to improved cognition, increased wakefulness, and decreased weight in patients with&#xD;
      schizophrenia who are on stable antipsychotic regimens&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was withdrawn due to no source of funding to implement the study. No participants&#xD;
      were enrolled for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No source of funding to implement the study.&#xD;
  </why_stopped>
  <start_date>February 2008</start_date>
  <completion_date type="Anticipated">June 2012</completion_date>
  <primary_completion_date type="Anticipated">January 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cognitive changes as measured by the NIH MATRICS - Consensus Cognitive Battery (MCCB)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Study withdrawn due to lack of funds.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sedation and weight changes</measure>
    <time_frame>8 weeks</time_frame>
    <description>Study withdrawn due to lack of funds.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>One arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study withdrawn due to lack of funds.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>modafinil</intervention_name>
    <description>Modafinil up to 400 mg daily will be added to a stable antipsychotic regimen</description>
    <arm_group_label>One arm</arm_group_label>
    <other_name>Provigil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnostic and Statistical Manual-IV diagnosis of schizophrenia (all subtypes),&#xD;
             illness duration greater than three years&#xD;
&#xD;
          -  Auditory and visual acuity adequate to complete cognitive tests&#xD;
&#xD;
          -  Stable dose of antipsychotics for at least 2 weeks prior to entry&#xD;
&#xD;
          -  Good physical health determined by complete physical examination, laboratory tests,&#xD;
             and EKG&#xD;
&#xD;
          -  Capacity and willingness to give written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to read or speak English&#xD;
&#xD;
          -  Documented disease of the central nervous system&#xD;
&#xD;
          -  History of intellectual impairment pre-dating onset of symptoms of psychosis (e.g.&#xD;
             mental retardation)&#xD;
&#xD;
          -  Clinically significant or unstable cardiovascular, renal, hepatic, gastrointestinal,&#xD;
             pulmonary or hematologic conditions;&#xD;
&#xD;
          -  HIV positive&#xD;
&#xD;
          -  Patients on antidepressants, including monoamine oxidase inhibitors&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Patients with a current diagnosis of substance dependence&#xD;
&#xD;
          -  Significant history of violence&#xD;
&#xD;
          -  History of an eating disorder&#xD;
&#xD;
          -  Ready for discharge within the following 8 weeks.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Pierre Lindenmayer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Manhattan Psychiatric Center</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <reference>
    <citation>Saavedra-Velez C, Yusim A, Anbarasan D, Lindenmayer JP. Modafinil as an adjunctive treatment of sedation, negative symptoms, and cognition in schizophrenia: a critical review. J Clin Psychiatry. 2009 Jan;70(1):104-12. Epub 2008 Nov 18. Review.</citation>
    <PMID>19026265</PMID>
  </reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>February 5, 2009</study_first_submitted>
  <study_first_submitted_qc>February 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2009</study_first_posted>
  <last_update_submitted>October 9, 2020</last_update_submitted>
  <last_update_submitted_qc>October 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Manhattan Psychiatric Center</investigator_affiliation>
    <investigator_full_name>Jean-Pierre Lindenmayer</investigator_full_name>
    <investigator_title>Study Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Schizophrenia</keyword>
  <keyword>Cognition</keyword>
  <keyword>Obesity</keyword>
  <keyword>Sedation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Modafinil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

